Discovery of IDO1 inhibitors: from bench to bedside
Small-molecule inhibitors of indoleamine 2, 3-dioxygenase-1 (IDO1) are emerging at the
vanguard of experimental agents in oncology. Here, pioneers of this new drug class provide …
vanguard of experimental agents in oncology. Here, pioneers of this new drug class provide …
Indoleamine 2, 3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
GC Prendergast, C Smith, S Thomas… - Cancer immunology …, 2014 - Springer
Genetic and pharmacological studies of indoleamine 2, 3-dioxygenase (IDO) have
established this tryptophan catabolic enzyme as a central driver of malignant development …
established this tryptophan catabolic enzyme as a central driver of malignant development …
Regulation of breast cancer metastasis signaling by miRNAs
Despite the decline in death rate from breast cancer and recent advances in targeted
therapies and combinations for the treatment of metastatic disease, metastatic breast cancer …
therapies and combinations for the treatment of metastatic disease, metastatic breast cancer …
Mass spectrometry, review of the basics: ionization
Mass spectrometry (MS) has become an integral tool in life sciences. The first step in MS
analysis is ion formation (ionization). Many ionization methods currently exist; electrospray …
analysis is ion formation (ionization). Many ionization methods currently exist; electrospray …
Inflammatory reprogramming with IDO1 inhibitors: turning immunologically unresponsive 'cold'tumors 'hot'
We discuss how small-molecule inhibitors of the tryptophan (Trp) catabolic enzyme
indoleamine 2, 3-dioxygenase (IDO) represent a vanguard of new immunometabolic …
indoleamine 2, 3-dioxygenase (IDO) represent a vanguard of new immunometabolic …
[HTML][HTML] Cadmium and breast cancer–current state and research gaps in the underlying mechanisms
Cadmium (Cd), a heavy metal with strong carcinogenic properties has been linked with
breast cancer risk. Epidemiological data on the association between Cd exposure and …
breast cancer risk. Epidemiological data on the association between Cd exposure and …
[HTML][HTML] Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation
GH Rauscher, JK Kresovich, M Poulin, L Yan, V Macias… - BMC cancer, 2015 - Springer
Background Breast cancer formation is associated with frequent changes in DNA
methylation but the extent of very early alterations in DNA methylation and the biological …
methylation but the extent of very early alterations in DNA methylation and the biological …
[HTML][HTML] Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer
R Radpour, Z Barekati, C Kohler, Q Lv, N Bürki… - PloS one, 2011 - journals.plos.org
Background Aberrant DNA methylation patterns might be used as a biomarker for diagnosis
and management of cancer patients. Methods and Findings To achieve a gene panel for …
and management of cancer patients. Methods and Findings To achieve a gene panel for …
DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells
M Chimonidou, A Strati, A Tzitzira… - Clinical …, 2011 - academic.oup.com
BACKGROUND Circulating tumor cells (CTCs) are associated with prognosis in a variety of
human cancers and have been proposed as a liquid biopsy for follow-up examinations. We …
human cancers and have been proposed as a liquid biopsy for follow-up examinations. We …
Aberrant methylation patterns in cancer: a clinical view
A Videtic Paska, P Hudler - Biochemia medica, 2015 - hrcak.srce.hr
Sažetak Epigenetic mechanisms, such as DNA methylation, DNA hydroxymethylation, post-
translational modifications (PTMs) of histone proteins affecting nucleosome remodelling …
translational modifications (PTMs) of histone proteins affecting nucleosome remodelling …